ROCKVILLE, Md., Feb. 16, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced today that Jeffrey Riley, President & Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat with the Company’s covering analyst, Adnan Butt, at the 2016 RBC Capital Markets Global Healthcare Conference on Tuesday, February 23, at 4:35 p.m. (ET) in the Holmes II room at the New York Palace Hotel in New York.
A live webcast of Synthetic Biologics’ fireside chat may be accessed by logging onto the internet at https://www.veracast.com/webcasts/rbc/healthcare2016/17116241334.cfm. After the discussion, a replay will be archived and accessible for 90 days at the same website.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company’s lead candidates in Phase 2 development include: (1) SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). In collaboration with Intrexon Corporation (NYSE: XON), the Company is developing a preclinical stage monoclonal antibody for the prevention and treatment of Pertussis, and discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics’ website at www.therivabio.com.
Logo – https://photos.prnewswire.com/prnh/20160105/319502LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-participate-in-fireside-chat-at-rbc-capital-markets-global-healthcare-conference-300220874.html
SOURCE Synthetic Biologics, Inc.
Released February 16, 2016